Value
4.9/10data confidence 100%| Component | Sub-score |
|---|---|
| P/E | 4.3 |
| P/S | 6.4 |
| EV/EBITDA | 0.0 |
| Fwd P/E | 5.5 |
| PEG | 5.7 |
| Analyst target | 6.0 |
- ▸Forward P/E: 23.1x
- ▸PEG: 1.33
DXCM · Why this verdict
Why DexCom (DXCM) is rated BUY WAIT
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictBUY WAIT
Overall score6.3/10
ConfidenceMEDIUM
MacroNEUTRAL
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
A wide economic moat, operating margins of 19%, a return on equity of 36%, and a perfect Piotroski F-Score of 9 out of 9 identify this as a business with durable competitive advantages that has compounded returns consistently across multiple periods. Quality breakdown | Operating margins remain above 15% and return on equity stays above 25% for the next four quarters, confirming the durability of the quality franchise. | →Stable |
| CounterRevenue concentration in a single product platform means a competitive displacement event or reimbursement rate change could erode margins rapidly; the moat's durability depends entirely on product-category dominance, which remains undiversified. | ||
At $74.22, the stock sits just 3.3% below the analyst consensus target of $76.69, leaving insufficient near-term margin of safety; the risk/reward at the current price does not clear the minimum asymmetry bar, and the setup favors a patient entry near $64 where the geometry is materially more attractive. Warnings | Analyst consensus price targets rise above $90, restoring more than 20% upside from the current price and justifying a position at current levels. | →Stable |
| CounterHigh-quality businesses with wide moats can sustain above-target valuations for extended periods when fundamental momentum is strong; the four-quarter beat streak and positive analyst sentiment may support a target revision upward before any pullback materializes. | ||
The company has beaten earnings estimates in each of the last four quarters with an average positive surprise of approximately 10%, demonstrating consistent execution and a pattern of setting expectations below what the business routinely delivers. Earnings | The beat streak extends for at least two additional quarters with positive earnings surprises above 5%, sustaining the established over-delivery pattern. | →Stable |
| CounterBeating estimates consistently can set an increasingly demanding bar; as analyst models incorporate the beat pattern, future estimates rise and the positive surprise buffer narrows — the same discipline that produced prior beats may be insufficient against higher expectations. | ||
Revenue is concentrated in a single product platform and the supply chain relies on single- or sole-source suppliers, creating binary downside risk if either the core product faces competitive disruption or a key supplier relationship is impaired. Bear case | Revenue from a second meaningful product category exceeds 15% of total sales for 2 consecutive quarters, demonstrating meaningful portfolio diversification. | →Stable |
| CounterThe wide economic moat — explicitly cited in the quality assessment — implies the single-product concentration reflects a defensible market leadership position rather than vulnerability; dominant platforms often appear concentrated precisely because they have captured the majority of the market. | ||
A wide economic moat, operating margins of 19%, a return on equity of 36%, and a perfect Piotroski F-Score of 9 out of 9 identify this as a business with durable competitive advantages that has compounded returns consistently across multiple periods.
→StableQuality breakdown
- Expectation
- Operating margins remain above 15% and return on equity stays above 25% for the next four quarters, confirming the durability of the quality franchise.
CounterRevenue concentration in a single product platform means a competitive displacement event or reimbursement rate change could erode margins rapidly; the moat's durability depends entirely on product-category dominance, which remains undiversified.
At $74.22, the stock sits just 3.3% below the analyst consensus target of $76.69, leaving insufficient near-term margin of safety; the risk/reward at the current price does not clear the minimum asymmetry bar, and the setup favors a patient entry near $64 where the geometry is materially more attractive.
→StableWarnings
- Expectation
- Analyst consensus price targets rise above $90, restoring more than 20% upside from the current price and justifying a position at current levels.
CounterHigh-quality businesses with wide moats can sustain above-target valuations for extended periods when fundamental momentum is strong; the four-quarter beat streak and positive analyst sentiment may support a target revision upward before any pullback materializes.
The company has beaten earnings estimates in each of the last four quarters with an average positive surprise of approximately 10%, demonstrating consistent execution and a pattern of setting expectations below what the business routinely delivers.
→StableEarnings
- Expectation
- The beat streak extends for at least two additional quarters with positive earnings surprises above 5%, sustaining the established over-delivery pattern.
CounterBeating estimates consistently can set an increasingly demanding bar; as analyst models incorporate the beat pattern, future estimates rise and the positive surprise buffer narrows — the same discipline that produced prior beats may be insufficient against higher expectations.
Revenue is concentrated in a single product platform and the supply chain relies on single- or sole-source suppliers, creating binary downside risk if either the core product faces competitive disruption or a key supplier relationship is impaired.
→StableBear case
- Expectation
- Revenue from a second meaningful product category exceeds 15% of total sales for 2 consecutive quarters, demonstrating meaningful portfolio diversification.
CounterThe wide economic moat — explicitly cited in the quality assessment — implies the single-product concentration reflects a defensible market leadership position rather than vulnerability; dominant platforms often appear concentrated precisely because they have captured the majority of the market.
TrendMatrix Research · core thesis
Engine thesis — one sentence
DexCom is a high-quality franchise with a wide economic moat, best-in-class margins, and four consecutive earnings beats, but the stock's current price leaves only 3.3% upside to the analyst target; the thesis favors a patient entry near $64 rather than initiating at current levels where the near-term risk/reward does not clear the minimum bar.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Per-dimension breakdown
Quality
8.4/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 10.0 |
| ROA | 6.4 |
| Gross margin | 8.3 |
| Op margin | 8.6 |
| Net margin | 9.7 |
| Current ratio | 6.8 |
| FCF quality | 7.7 |
| Moat | 8.2 |
| Piotroski F | 10.0 |
- ▸Excellent ROE: 36%
- ▸Strong margins: 19%
- ▸Wide economic moat
- ▸Compounder quality: strong returns + growth
Growth
8.1/10data confidence 67%| Component | Sub-score |
|---|---|
| Rev growth | 6.2 |
| EPS growth | 10.0 |
Momentum
3.7/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 7.5 |
| MACD | 0.0 |
| OBV | 5.0 |
| MA position | 5.0 |
| Volume | 0.9 |
- ▸Uptrend pullback (RSI 40) - buy opportunity
- ▸Above 200-MA but MA slope flat
Sentiment
7.5/10data confidence 100%| Component | Sub-score |
|---|---|
| Analyst rating | 9.0 |
| Price target | 7.6 |
| erm sentiment | 5.3 |
Insider
5.0/10data confidence 50%| Component | Sub-score |
|---|---|
| materiality | 5.0 |
| holder change | 5.1 |
- ▸Insider selling (low materiality) — $3,343,996 (0.012% of mkt cap)
Peer rank
4.7/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 3.4 |
| quality rank | 9.5 |
| growth rank | 6.1 |
- ▸Superior ROE vs peers
- ▸Best-in-class margins
Technical
6.0/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 5.6 |
| support resistance | 6.6 |
| 52w position | 5.8 |
Risk (lower is worse)
6.3/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 7.5 |
| days to cover | 8.4 |
| volatility | 3.9 |
| put call | 6.9 |
| implied vol | 4.0 |
| beta | 5.2 |
| debt equity | 8.1 |
- ▸Concentration risks: 2 HIGH (10-K Item 1A — sized via position_sizing, validated via buy_confidence)
Catalyst
6.8/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 10.0 |
| earnings timing | 5.0 |
| surprise avg | 7.4 |
- ▸Perfect beat streak: 4Q
How the verdict was assembled
Engine trigger
Growth is cheap relative to earnings, but the technical setup has not yet produced a breakout above resistance (PEG 1.33, quality 8.4/10, growth 8.1/10).
Engine technical detail
verdict_path:
L4:PATH_C2_GARP_WAIT|ENTRY_STICKY:PRIOR_STILL_VIABLEPassed (6)
- INSIDER:OK
- 8K:CLEAN
- NEWS_EVENTS:NONE_RECENT
- EARNINGS_PROXIMITY:24d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (2)
- MOMENTUM:3.7<4.5
- ASYMMETRY:1.1<1.5@spot
Warning (0)
none
Reward-to-Risk
1.11
Upside
+7.7%
Downside
6.9%
Sizing output
STARTER
Setup— — No clear chart pattern; technical signals are mixed
EdgeTemporary headwind — High quality (8.4) with weak momentum (3.7)
SuitabilityAggressive — Beta 1.45>1.3
Investment implication
The C-path quality+growth combination triggered the STRONG_BUY_WAIT verdict: quality 8.4 and growth 8.1 both clear their thresholds, with asymmetric R:R of 1.11 supporting the read.
The strongest dimensions are Quality at 8.4, Growth at 8.1, and Sentiment at 7.5; the weakest are Momentum at 3.7, Peer rank at 4.7, and Value at 4.9. The V9 engine flagged 2 failed gates, producing an asymmetric reward-to-risk of 1.11 and an engine sizing output of STARTER.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Wide Economic Moat And Compounder Quality
Trip ifOperating margin compresses below 10% from the current 19% for 2 consecutive quarters, signaling a structural erosion in the quality franchise.
- P2Four Consecutive Earnings Beats
Trip ifEPS surprise falls below 0% for 2 consecutive quarters, ending the four-quarter beat streak.
- P3Thin Upside At Current Price Level
Trip ifAnalyst consensus price target rises above $90 from the current $76.69, restoring more than 20% upside from the current stock price.
- P4Product And Supplier Concentration Risk
Trip ifRevenue concentration from the core product platform falls below 80% of total revenue for 2 consecutive quarters, indicating meaningful diversification has begun.